AVAV Deadline: AVAV Investors with Losses in Excess of $100K Have Opportunity to Lead AeroVironment, Inc. Securities Fraud Lawsuit

PR Newswire

NEW YORK, June 28, 2026 /PRNewswire/ —

Rosen Law Firm Logo

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AeroVironment, Inc. (NASDAQ: AVAV) between June 25, 2025 and March 10, 2026, inclusive (the “Class Period”), of the important July 27, 2026 lead plaintiff deadline.

So What: If you purchased AeroVironment securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the AeroVironment class action, go to https://rosenlegal.com/cases/aerovironment-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) AeroVironment understated the likelihood that it would imminently face competition from other vendors for the work it performed in connection with the U.S. Space Force’s Satellite Communication Augmentation Resources (“SCAR”) program and the U.S. Space Force’s ongoing efforts to modernize the Satellite Control Network (“SCN”); (2) accordingly, defendants overstated AeroVironment’s business and financial prospects; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the AeroVironment class action, go to https://rosenlegal.com/cases/aerovironment-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avav-deadline-avav-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-aerovironment-inc-securities-fraud-lawsuit-302812129.html

SOURCE THE ROSEN LAW FIRM, P. A.

BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia

– Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant improvement versus placebo (LS mean +0.37 SD; p<0.0001), the first and only statistically significant placebo-controlled arm span result reported for an achondroplasia trial at 52 weeks

– This is the first and only Phase 3 data for an achondroplasia clinical study published in The New England Journal of Medicine (NEJM), marking BridgeBio’s second NEJM publication in achondroplasia and fourth NEJM publication overall in the last three years

– The data includes the largest mean increase in AHV compared to placebo reported in any Phase 3 achondroplasia study (+2.1 cm/year observed mean improvement)

– Oral infigratinib is the only therapy to demonstrate statistically significant improvement in body proportionality in a Phase 3 achondroplasia study, with a LS mean treatment difference of –0.05 in children ages 3 to 8 years (p<0.05)


Oral infigratinib was well tolerated, with no discontinuations or serious adverse events related to study drug

– BridgeBio
intends to submit an NDA to the FDA in the third quarter of 2026 with launch anticipated in early to mid 2027, and an MAA to the EMA in the second half of 2026

PALO ALTO, Calif., June 28, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that positive results from PROPEL 3, the global Phase 3 pivotal study of oral infigratinib in children living with achondroplasia, were published as an original research article in the New England Journal of Medicine (NEJM). These data were also presented at the International Congress of Children’s Bone Health (ICCBH) 2026 in a late-breaking oral presentation by Ravi Savarirayan, M.D., Ph.D. of Murdoch Children’s Research Institute, Melbourne, AUS, and global lead investigator for PROPEL 3.

“The publication of our pivotal trial data (PROPEL 3) in the New England Journal of Medicine is a defining milestone for the field of skeletal dysplasia that reflects the years of rigorous clinical investigation from investigators and dedication from children and their families to make this breakthrough science possible. These remarkable data establish oral infigratinib as the first therapy to directly target FGFR3, deliver the highest treated annualized growth velocity and greatest improvement in body proportionality reported for any current therapy for children with achondroplasia. Presenting these late-breaking data at ICCBH reflects the significance of having an orally administered, mechanistically distinct treatment option that addresses achondroplasia and hypochondroplasia at their very source,” said Dr. Savarirayan. “I believe that we are on a clear path toward a best-in-class therapy for children with achondroplasia that families seeking better options are excited to have available to them.”

The positive results shared in NEJM from PROPEL 3 include:

  • PROPEL 3 successfully met the primary endpoint of change from baseline in annualized height velocity, with a LS mean treatment difference against placebo of +1.74 cm/yr (p<0.0001). The observed mean difference was +2.10 cm/yr (p<0.0001). Both values are the largest observed in a Phase 3 clinical study in achondroplasia
  • PROPEL 3 successfully met the key secondary endpoint of change from baseline in height Z-score (achondroplasia reference population) at Week 52 (p<0.0001), with an LS mean increase on the treatment arm of +0.41 SD
  • In a pre-specified exploratory analysis of the key secondary endpoint, oral infigratinib achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia, demonstrating an LS mean treatment difference of -0.05 (p<0.05) against placebo in children younger than 8 years old (>50% of the participants)
  • Infigratinib was well-tolerated, with:
    • No discontinuations related to study drug
    • No serious adverse events related to study drug
    • 3 cases (4%) of hyperphosphatemia, all mild, transient, asymptomatic, and not requiring dose reductions or discontinuations
    • No adverse events associated with inhibition of FGFR1 or FGFR2 (e.g., retinal or corneal)
  • Additional data presented at ICCBH showed infigratinib improved arm span vs. placebo by +0.37 SD (p<0.0001), marking the first statistically significant improvement in arm span from a placebo-controlled achondroplasia trial

In addition to the late-breaking oral presentation at ICCBH 2026, one oral presentation, one poster, and three encore posters were shared. The new details shared included:

  • Health-Related Quality of Life in Children with Achondroplasia: Findings from the Observational PROPEL Study, presented by Marie-Eve Robinson, M.D., of Shriners Hospital for Children Canada, McGill University, Montreal, CA

    • Results from the global observational PROPEL study demonstrated that children with achondroplasia experience reduced health-related quality of life across multiple patient-reported measures, particularly in physical functioning, reinforcing the significant day-to-day burden of the condition and providing important baseline context for future studies of oral infigratinib
  • Qualitative Research to Evaluate the Content Validity and Relevance of Patient-Reported Outcome Measures for Children and Parents of Children with Hypochondroplasia, presented by Chandler Crews of The Chandler Project, U.S.

    • Findings from interviews with children and parents affected by hypochondroplasia demonstrated that commonly used patient-reported outcome measures were clear, relevant, and reflective of the real-world physical, cognitive, and quality-of-life challenges experienced by children living with the condition, supporting their use in future clinical research and care

BridgeBio believes oral infigratinib is positioned to become the first approved oral therapy and a potential best-in-class option for children living with achondroplasia and hypochondroplasia. The Company intends to submit an NDA for achondroplasia to the FDA in the third quarter of 2026, and an MAA for achondroplasia to the EMA in the second half of 2026. The Company anticipates a U.S. launch in early to mid 2027.

Oral infigratinib has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on the shared results from the PROPEL 2 clinical trial, which meet the FDA’s requirement of potentially demonstrating substantial improvement in efficacy over available therapies on clinically significant endpoints. In addition to receipt of Breakthrough Therapy Designation, oral infigratinib has also received Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation for achondroplasia from the FDA. If infigratinib is approved, BridgeBio may qualify for a Priority Review Voucher.

Information about PROPEL Infant & Toddler trial (NCT07169279) can be found here on clinicaltrials.gov. Information about ACCEL, the Company’s observational lead-in study for oral infigratinib in hypochondroplasia’s Phase 3 study, (NCT06410976) can be found here, and information about ACCEL 2/3, BridgeBio’s Phase 2/3 clinical study of oral infigratinib in hypochondroplasia, (NCT06873035) can be found here. BridgeBio is committed to exploring the potential of oral infigratinib on wider medical and functional impacts of achondroplasia, hypochondroplasia and other skeletal dysplasia conditions, which hold significant unmet needs for families.

About Achondroplasia

Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the U.S. and European Union (EU), including up to 10,000 children and adolescents with open growth plates. Achondroplasia impacts overall health and quality of life, leading to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis. The condition is uniformly caused by an activating variant in FGFR3.

About Oral Infigratinib

Oral infigratinib is an investigational small molecule designed to inhibit FGFR3 signaling and target skeletal dysplasias, including achondroplasia and hypochondroplasia, at their source. Overactivating FGFR3 pathogenic variants drive downstream MAPK and STAT1 signaling that aberrates growth plate development, thereby causing disproportionate short stature and the potential for serious health complications. Oral infigratinib improves bone growth by decreasing the overactivity of FGFR3.

About BridgeBio Pharma, Inc.

BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedInXFacebookInstagramYouTube, and TikTok.

BridgeBio Pharma, Inc. Forward-Looking Statements

This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues”, “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains”, “seeks,” “should,” “will,” and variations of such words or similar expressions, or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements, including express and implied statements relating to our expectations regarding the potential approval of oral infigratinib for achondroplasia; the timing of a potential NDA submission to the FDA and MAA submission to the EMA for achondroplasia and a potential launch of oral infigratinib; the potential of oral infigratinib to become the first approved oral therapy and a potential best-in-class option for children living with achondroplasia and hypochondroplasia; the potential of oral infigratinib to address achondroplasia, hypochondroplasia and other skeletal dysplasia conditions at their source and with respect to wider medical and functional impacts; the potential use of findings from our observational and qualitative research in future clinical research and care; and our potential qualification for a Priority Review Voucher if oral infigratinib is approved, reflect our current views about our plans, intentions, expectations and strategies, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from our preclinical studies and clinical trials not being indicative of final data, the potential size of the target patient populations our product candidates are designed to treat not being as large as anticipated, the design and success of ongoing and planned clinical trials, difficulties with enrollment in our clinical trials, adverse events that may be encountered in our clinical trials, future regulatory filings, approvals and/or sales, despite having ongoing and future interactions with the FDA or other regulatory agencies to discuss potential paths to registration for our product candidates, the FDA or such other regulatory agencies not agreeing with our regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted, the continuing success of our collaborations, our ability to obtain additional funding, potential volatility in our share price, the impacts of current macroeconomic and geopolitical events, including changing conditions from the hostilities in Ukraine and the Middle East, increasing rates of inflation and changing interest rates, on our overall business operations and expectations, as well as those risks set forth in the Risk Factors section of our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and our other filings with the U.S. Securities and Exchange Commission. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

BridgeBio Media Contact:

Bubba Murarka, Executive Vice President
[email protected]
(650)-789-8220

BridgeBio Investor Contact:

Chinmay Shukla, Senior Vice President, Strategic Finance
[email protected]



After the SpaceX IPO, Investors Are Looking Past Launch — to the Companies That Sell What Satellites See

Editorial Commentary — Commercial Space Series

SpaceX’s listing put rockets and broadband in the spotlight, but the data layer of the space economy is its own market. Planet Labs (NYSE: PL) sells daily Earth-imagery and analytics, with record revenue and a fast-growing backlog.

VANCOUVER, British Columbia, June 28, 2026 (GLOBE NEWSWIRE) — Energy Metal News Market Commentary, the public listing of Space Exploration Technologies Corp. (NASDAQ: SPCX) — There is a third layer to the space economy that is easy to overlook and increasingly valuable in its own right — the data. Once satellites are in orbit, what they observe about the Earth below becomes a sellable product, and an entire category of public companies exists to capture, refine, and sell that information. Get our free Orbital Economy Signal Brief for plain-English intelligence on the commercial-space sector, delivered as it moves.

Key Takeaways

  • The SpaceX IPO drew attention to launch and satellite broadband — but the Earth-observation data layer is a distinct, subscription-driven market with its own public names.
  • Planet Labs PBC (NYSE: PL) reported record quarterly revenue of about US$94 million, up 42% year-over-year, for the quarter ended April 30, 2026, with backlog above US$906 million.
  • Planet ended the period with cash and short-term investments up 223% year-over-year to about US$731 million, and raised full-year revenue guidance to roughly US$425–441 million.
  • Other listed Earth-observation and satellite-data names include Satellogic (Nasdaq: SATL) and BlackSky (NYSE: BKSY) — each distinct, and neither a proxy for the other.

The Part of the Space Economy the IPO Headlines Missed

This is the Earth-observation layer, and it behaves less like a rocket business and more like a software-and-data subscription business — recurring revenue, high gross margins, and customer relationships that compound over time. As the SpaceX IPO pushes investors to map the full space value chain, the data layer stands out as the part with the most familiar, and arguably most durable, business model. The most prominent public name in it is Planet Labs.

Planet Labs: Selling a Daily Picture of the Planet

Planet Labs PBC (NYSE: PL), based in San Francisco, operates one of the largest fleets of imaging satellites in the world, capturing daily, high-resolution imagery of the Earth and selling that data — plus AI-enabled analytics built on top of it — by subscription to governments, defense and intelligence agencies, agriculture, energy, insurance, and environmental customers. Its model is the inverse of a launch company’s: rather than selling a one-time trip to orbit, it sells an ongoing, ever-refreshing stream of information about change on the ground.

The financials have started to reflect that model maturing. For the quarter ended April 30, 2026 — its fiscal first quarter of 2027 — Planet reported record revenue of about US$94 million, up 42% year-over-year, with remaining performance obligations up 81% and backlog above US$906 million. The company ended the period with cash and short-term investments up 223% year-over-year to roughly US$731 million, and raised full-year revenue guidance to approximately US$425–441 million while pointing toward adjusted-EBITDA profitability. It also continued deploying its next-generation, higher-resolution Pelican satellites, including one carrying Sweden’s first sovereign reconnaissance payload.

The risks are characteristic of the category: Planet has historically operated at a net loss as it invested in its constellation, it carries meaningful exposure to government and defense budgets and procurement timing, and it faces real competition in a field where imagery is increasingly abundant. Record revenue and a strengthening balance sheet improve the picture, but profitability at scale still has to be demonstrated, not assumed.

Why the Data Layer Benefits From the Whole Sector’s Growth

There is a structural reason Earth-observation companies stand to gain from the post-SpaceX-IPO environment, and it is almost mechanical: cheaper, more frequent launch — the very thing SpaceX pioneered and Rocket Lab and others are extending — lowers the cost of putting imaging satellites into orbit and refreshing constellations. The launch layer is, in effect, the cost base for the data layer. As access to space gets cheaper and more routine, the economics of operating a large imaging fleet improve, and the data those fleets produce gets cheaper to generate and richer in coverage. In that sense, a data company like Planet is a downstream beneficiary of the same forces the SpaceX listing has spotlighted — it sells the output of an infrastructure that is getting cheaper to build. Tracking how this sector is being repriced in real time? Join the free Orbital Economy Signal Brief to follow the shifts as they happen.

The Wider Earth-Observation Field

A couple of other listed companies populate the Earth-observation and satellite-data landscape — each with a distinct focus and risk profile, and neither a proxy for the other. Satellogic (Nasdaq: SATL) is a vertically integrated geospatial-intelligence company pursuing high-resolution Earth observation at low cost; it reported first-quarter 2026 revenue up 80% year-over-year, off a small base, as it expands defense and intelligence partnerships. BlackSky Technology (NYSE: BKSY) focuses on rapid-revisit, very-high-resolution imagery and a software platform that turns it into geospatial intelligence for government and commercial customers, anchoring the real-time-tasking end of the market. Together with Planet, these names show that “space data” spans optical imagery and geospatial intelligence — subscription-oriented businesses being re-rated alongside the broader sector, even as each depends on its own constellation, customers, and path to profitability.

A Newer Public Entrant Worth Noting

Investors tracking newer public entrants may also note Starfighters Space, Inc. (NYSE American: FJET), included here for context only and not as a recommendation. The company, which completed its IPO in December 2025, announced that it was added to the broad-market Russell 3000 Index effective June 29, 2026, as part of the index’s 2026 reconstitution. Starfighters has said it operates a fleet of supersonic F-104 aircraft from NASA’s Kennedy Space Center and continues to develop its STARLAUNCH air-launch platform. As with all names here, these are the company’s own disclosures and should be verified independently.

The Bottom Line

The SpaceX IPO trained the market’s eye on rockets and broadband, but the space economy is a stack, and its data layer may be its most software-like, most recurring, and most overlooked tier. Planet Labs is the most prominent public way to own that layer, with record revenue, a growing backlog, and a strengthening balance sheet — set against the profitability and competition risks that still define the category. As cheaper launch makes orbit more accessible, the companies that sell what satellites see stand to benefit from the same wave lifting the launchers. For investors building a complete map of the post-IPO space economy, the data layer belongs on it — with each name judged, as always, on its own numbers. To keep a closer eye on the launch, satellite, lunar, and space-data economy as it develops, sign up for the free Orbital Economy Signal Brief.

SIGNAL OVER NOISE

Signal over noise. Space, Earth-observation, and data headlines move fast — and the crowd often moves first. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they happen, so you see the move forming instead of reading about it later. See it at eagle-eye.dev.

CONTACT

Energy Metal News
[email protected]

SOURCES

[1] Space Exploration Technologies Corp. (SpaceX), Form S-1 registration statement (proposed Nasdaq symbol SPCX), May–June 2026, sec.gov; contemporaneous reporting.
[2] Planet Labs PBC (NYSE: PL), Q1 fiscal 2027 results (quarter ended April 30, 2026; record revenue, backlog, cash, raised guidance), June 4, 2026.
[3] Satellogic Inc. (Nasdaq: SATL), Q1 2026 financial results, May 11, 2026.
[4] BlackSky Technology Inc. (NYSE: BKSY), corporate and product disclosures, 2026.
[5] Starfighters Space, Inc. (NYSE American: FJET), company press releases (Russell 3000 Index inclusion effective June 29, 2026; December 2025 IPO; STARLAUNCH), 2026.

DISCLAIMER

IMPORTANT — PLEASE READ: This article is editorial commentary and was NOT paid for, requested, commissioned, reviewed, or approved by any of the companies named in it, nor by Creative Direct Marketing Group (“CDMG”). No company mentioned in this article paid for or had any involvement in its preparation or publication. The disclosures that follow are provided in the interest of full transparency regarding our broader business relationships, even though they do not apply to this specific article.

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This publication is neither an offer nor a recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Energy Metal News is owned and operated by Market IQ Media Group Limited, a company incorporated under the laws of Ireland (“MIQL”). As part of its ongoing business, MIQL has been paid fees by CDMG for advertising and digital media for Starfighters Space, Inc. (NYSE American: FJET) in connection with separate, paid campaigns; those paid materials are distinct from this article, which is unpaid editorial. This relationship constitutes a potential conflict of interest as to our ability to remain objective in our commentary regarding Starfighters Space, Inc., and readers are strongly encouraged not to use this publication as the basis for any investment decision. MIQL and its owner/operators do not own shares of Starfighters Space, Inc. or of any other company named in this article in connection with this piece, but reserve the right to buy and sell securities of any company mentioned at any time without further notice. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our publication is not trustworthy unless verified by their own independent research. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

FORWARD-LOOKING STATEMENTS: This publication contains forward-looking statements concerning the companies referenced and the commercial-space sector, including statements regarding the proposed initial public offering of Space Exploration Technologies Corp. (“SpaceX”) and its reported terms, which are based on third-party reporting and SpaceX’s own filings and remain subject to change until and unless finalized; product development, launch and mission timelines; contract awards and backlog; and broader market conditions. Forward-looking statements are not guarantees of future results and are subject to risks and uncertainties — including execution, regulatory, financing, competitive and macroeconomic risks — that could cause actual results to differ materially, as detailed in each referenced company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov. References to SpaceX are for thematic and contextual purposes only; SpaceX is a separate company with no affiliation to the publisher, and nothing herein is an offer to buy or sell, or a solicitation of any offer to buy or sell, securities of SpaceX or any other company. Figures attributed to named companies are drawn from those companies’ public disclosures. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made; the publisher undertakes no obligation to update or revise them except as required by applicable law.



BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit

PR Newswire

NEW YORK, June 27, 2026 /PRNewswire/ —

Rosen Law Firm Logo

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Badger Meter, Inc. (NYSE: BMI) between April 18, 2024 and April 16, 2026, inclusive (the “Class Period”), of the important August 3, 2026 lead plaintiff deadline.

So what: If you purchased Badger Meter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Badger Meter class action, go to https://rosenlegal.com/cases/badger-meter-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 3, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements concerning the drivers of Badger Meter’s “record” financial results, demand for Badger Meter’s products, and its prospects for continued growth. During the Class Period, defendants told investors that Badger Meter’s strong financial results reflected “ongoing favorable industry trends,” “secular growth drivers,” and “solid operating execution.” They likewise touted “strong” demand and said they were seeing “robust order pacing and a strong bid pipeline that positions us well for continued sales and earnings growth,” and that Badger Meter possessed a “long runway” for growth.

According to the lawsuit, these statements were materially false and misleading. In truth, Badger Meter’s financial results during the Class Period were at least partially attributable to Badger Meter’s practice of pulling-forward customer orders to recognize revenue early, which concealed weakening demand and deteriorating near-term order trends. This practice also depleted revenue otherwise available for future periods, ultimately causing the disappointing financial results Badger Meter later reported. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the Badger Meter class action, go to https://rosenlegal.com/cases/badger-meter-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bmi-investors-have-opportunity-to-lead-badger-meter-inc-securities-fraud-lawsuit-302812099.html

SOURCE THE ROSEN LAW FIRM, P. A.

The SpaceX IPO Lifted the Whole Space Economy — Including the Public Companies Building the Road Back to the Moon

PR Newswire

Editorial Commentary — Commercial Space Series

SpaceX

s listing drew investor attention to the broader space economy, including lunar infrastructure. Intuitive Machines (Nasdaq: LUNR) has emerged as a leading public name in NASA

s commercial Moon program, with record revenue and a US$1.1 billion backlog.

VANCOUVER, BC, June 27, 2026 /PRNewswire/ — American News Group Market Commentary, The public listing of Space Exploration Technologies Corp. (NASDAQ: SPCX) As the most valuable private enterprise in the world arrived on the public market, it reframed the entire space sector as an investable theme — and capital began searching for the listed names attached to each piece of the opportunity. Among the threads that drew fresh attention was one of the most evocative: the return to the Moon. Get our free Orbital Economy Signal Brief for plain-English intelligence on the commercial-space sector, delivered as it moves.

American News Group Logo

Key Takeaways

  • The SpaceX IPO reframed space as a public-market theme, and reporting noted a broad rally across space stocks tied to lunar and Moon-base initiatives.
  • Intuitive Machines (Nasdaq: LUNR) reported record Q1 2026 revenue of about US$186.7 million, nearly triple the prior year, with a backlog of about US$1.1 billion.
  • Growth was driven by its US$800 million Lanteris Space Systems acquisition and NASA and U.S. Space Force contracts, including selection for the Andromeda IDIQ with a ceiling reported up to US$6.2 billion.
  • Other listed names spanning lunar and space infrastructure include Voyager Technologies (NYSE: VOYG) and Boeing (NYSE: BA) — each distinct, and neither a proxy for the other.

From One Mega-IPO to a Sector-Wide Re-Rating

Reporting around the period noted a rally across space stocks tied to NASA’s lunar ambitions and Moon-base planning. SpaceX itself is central to that story — its Starship is integral to NASA’s Artemis program — but the lunar economy is being built by a wider set of companies, several of them already public. The one that has moved most decisively into that role is Intuitive Machines.

Intuitive Machines: A Lunar Pioneer Turning Into a Space Prime

Intuitive Machines (Nasdaq: LUNR), based in Houston, first drew headlines as a lunar-lander company — its Nova-C spacecraft became the first U.S. vehicle to soft-land on the Moon since Apollo. But its 2026 story is one of transformation from a single-mission lunar specialist into a vertically integrated, multi-domain space contractor. In the first quarter of 2026, the company reported record revenue of about US$186.7 million — nearly triple the prior-year period — alongside positive adjusted EBITDA of US$2.7 million and a contracted backlog of roughly US$1.1 billion.

The leap was powered by its roughly US$800 million acquisition of Lanteris Space Systems, which broadened the company well beyond landers, plus a run of government awards. Management described a revenue mix split across commercial, civil, and national-security customers, and pointed to milestones including a NASA Commercial Lunar Payload Services task order for its IM-5 mission and selection for the U.S. Space Force’s Andromeda IDIQ, a space-domain-awareness program with a ceiling reported as high as US$6.2 billion. The company reaffirmed full-year 2026 revenue guidance of US$900 million to US$1 billion.

As ever, the counterweight matters. Intuitive Machines carries concentrated exposure to government contracts and their appropriations timing, integration risk from rapid acquisitions, and the simple reality that lunar missions are difficult — its earlier landing famously tipped on touchdown while still returning data. The backlog provides visibility; it does not eliminate execution risk.

Why the Lunar Economy Is Suddenly an Investment Category

The deeper shift the SpaceX IPO helped surface is that “going to the Moon” has become a procurement program, not just an exploration goal. NASA’s Artemis effort and its associated Moon-base planning are designed to be executed substantially through commercial contracts — landers, terrain vehicles, communications relays, and surface infrastructure bought from private companies. That converts a national ambition into a recurring revenue opportunity for the firms positioned to win the work, and it is why a lunar-services company’s backlog and contract wins now read like those of any other government-exposed growth business. Intuitive Machines has leaned directly into that, expanding from landers into space-to-Earth data relay through planned acquisitions of ground-station assets, building toward the kind of integrated infrastructure the program will need for years. Tracking how this sector is being repriced in real time? Join the free Orbital Economy Signal Brief to follow the shifts as they happen.

The Wider Lunar-and-Infrastructure Field

A couple of other listed companies frame the broader infrastructure landscape around the lunar and space-services theme — each distinct, and neither a proxy for the other. Voyager Technologies (NYSE: VOYG) is a space-and-defense technology company working across propulsion, precision systems, and space-infrastructure programs, and has been awarded a series of defense and space contracts as it builds out its platform. Boeing (NYSE: BA) anchors the large-cap, incumbent end: a diversified aerospace-and-defense prime with deep space heritage spanning human spaceflight, satellites, and major NASA programs. It is the steadier, established route into the same broad theme, with none of the pure-play torque — or the pure-play risk — of a smaller name. Together they show a lunar-and-space-infrastructure trade that runs from focused specialists to century-old primes, all drawn closer to the spotlight as SpaceX’s listing re-rated the category — though each remains tied to its own contracts and execution.

Another Name in the Space-Access Field

Among the smaller, specialized names in the field is Starfighters Space, Inc. (NYSE American: FJET), referenced here purely for context and not as a recommendation. Over recent months the company has announced a series of partnership and development steps, including engaging Integrated Launch Solutions (ILS) to support mission design and range integration for its STARLAUNCH pathway, joining the NSF-proposed C-STARS research consortium at the University of Florida, and expanding a partnership with Mu-g Technologies on microgravity research. The company has said it is targeting a STARLAUNCH II space-demonstration flight over a roughly 18-to-24-month window, subject to regulatory approvals and execution. These are the company’s own publicly stated plans.

The Bottom Line

SpaceX’s arrival on the public market turned the space economy into a theme investors feel they must understand — and the road back to the Moon is one of its most tangible pieces. Intuitive Machines has positioned itself as a leading public name in that build-out, with record revenue, a billion-dollar-plus backlog, and a deliberate pivot from lunar lander to multi-domain space prime. The opportunity is real and contract-backed; so are the risks of government timing and acquisition integration. For investors drawn to the lunar story the SpaceX IPO helped illuminate, the names are now public and the milestones are now scheduled — with the data, as always, still to be delivered. To keep a closer eye on the launch, satellite, lunar, and space-data economy as it develops, sign up for the free Orbital Economy Signal Brief.

SIGNAL OVER NOISE

Signal over noise. Space, lunar, and defense headlines move fast — and the crowd often moves first. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they happen, so you see the move forming instead of reading about it later. See it at eagle-eye.dev.

CONTACT

American News Group
[email protected]

SOURCES

[1] Space Exploration Technologies Corp. (SpaceX), Form S-1 registration statement (proposed Nasdaq symbol SPCX), May–June 2026, sec.gov; contemporaneous reporting on space-sector reaction.
[2] Intuitive Machines, Inc. (Nasdaq: LUNR), Q1 2026 financial results (record revenue, US$1.1B backlog, Lanteris, Andromeda IDIQ, IM-5), May 2026.
[3] Voyager Technologies, Inc. (NYSE: VOYG), corporate and contract disclosures, 2026.
[4] The Boeing Company (NYSE: BA), corporate and space-program disclosures, 2026.
[5] Starfighters Space, Inc. (NYSE American: FJET), company press releases (Integrated Launch Solutions engagement; C-STARS; Mu-g partnership; STARLAUNCH II demonstration timeline), 2026.

DISCLAIMER

IMPORTANT — PLEASE READ: This article is editorial commentary and was NOT paid for, requested, commissioned, reviewed, or approved by any of the companies named in it, nor by Creative Direct Marketing Group (“CDMG”). No company mentioned in this article paid for or had any involvement in its preparation or publication. The disclosures that follow are provided in the interest of full transparency regarding our broader business relationships, even though they do not apply to this specific article.

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This publication is neither an offer nor a recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. American News Group is owned and operated by Market IQ Media Group Limited, a company incorporated under the laws of Ireland (“MIQL”). As part of its ongoing business, MIQL has been paid fees by CDMG for advertising and digital media for Starfighters Space, Inc. (NYSE American: FJET) in connection with separate, paid campaigns; those paid materials are distinct from this article, which is unpaid editorial. This relationship constitutes a potential conflict of interest as to our ability to remain objective in our commentary regarding Starfighters Space, Inc., and readers are strongly encouraged not to use this publication as the basis for any investment decision. MIQL and its owner/operators do not own shares of Starfighters Space, Inc. or of any other company named in this article in connection with this piece, but reserve the right to buy and sell securities of any company mentioned at any time without further notice. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our publication is not trustworthy unless verified by their own independent research. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

FORWARD-LOOKING STATEMENTS: This publication contains forward-looking statements concerning the companies referenced and the commercial-space sector, including statements regarding the proposed initial public offering of Space Exploration Technologies Corp. (“SpaceX”) and its reported terms, which are based on third-party reporting and SpaceX’s own filings and remain subject to change until and unless finalized; product development, launch and mission timelines; contract awards and backlog; and broader market conditions. Forward-looking statements are not guarantees of future results and are subject to risks and uncertainties — including execution, regulatory, financing, competitive and macroeconomic risks — that could cause actual results to differ materially, as detailed in each referenced company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov. References to SpaceX are for thematic and contextual purposes only; SpaceX is a separate company with no affiliation to the publisher, and nothing herein is an offer to buy or sell, or a solicitation of any offer to buy or sell, securities of SpaceX or any other company. Figures attributed to named companies are drawn from those companies’ public disclosures. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made; the publisher undertakes no obligation to update or revise them except as required by applicable law.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-spacex-ipo-lifted-the-whole-space-economy–including-the-public-companies-building-the-road-back-to-the-moon-302812547.html

The SpaceX IPO Put a Spotlight on Starlink — and on the One Public Company Building a Rival Direct-to-Phone Network

PR Newswire

Editorial Commentary — Commercial Space Series

SpaceX

s public listing cast Starlink Mobile as a future wireless challenger. AST SpaceMobile (NASDAQ: ASTS) is the most prominent publicly traded company pursuing the same direct-to-device satellite-broadband market.

Key Takeaways

  • The SpaceX IPO prospectus framed Starlink Mobile as a direct-to-smartphone service intended to compete with terrestrial mobile networks — spotlighting a market that public investors cannot access through SpaceX alone.
  • AST SpaceMobile (NASDAQ: ASTS) is the most prominent listed company building a direct-to-device satellite-broadband network, connecting ordinary, unmodified smartphones from space.
  • AST has reported securing over US$1.2 billion in aggregate contracted revenue commitments from partners, and is targeting 45 to 60 satellites in orbit by the end of 2026.
  • Other listed satellite-connectivity names include Globalstar (NASDAQ: GSAT) and Viasat (NASDAQ: VSAT) — each distinct, and neither a proxy for the other.

The IPO That Made Satellite-to-Phone a Headline

VANCOUVER, BC, June 27, 2026 /PRNewswire/ — Equity Insider Market Commentary, When Space Exploration Technologies Corp. (SpaceX) filed to go public on the Nasdaq under the proposed ticker SPCX, the prospectus did more than reveal the financials of the world’s most valuable private company. It laid out, in detail, how SpaceX intends to turn its Starlink constellation into a wireless competitor — casting Starlink Mobile as a direct-to-smartphone service designed to perform “on par with terrestrial mobile networks,” with next-generation satellites slated to expand the offering beyond messaging toward full broadband and IoT connectivity. Get our free Orbital Economy Signal Brief for plain-English intelligence on the commercial-space sector, delivered as it moves.

Equity Insider

That framing turned a once-niche idea — connecting an ordinary phone directly to a satellite, with no special hardware — into a front-page investment theme. But there is a catch for public investors: SpaceX’s satellite-to-phone business is bundled inside an enormous company spanning launch, Starlink broadband, and an artificial-intelligence unit. For those seeking a focused, public-market way to play the direct-to-device race specifically, the most prominent name is not SpaceX at all. It is AST SpaceMobile.

AST SpaceMobile: The Public Pure-Play on Phones-From-Space

AST SpaceMobile (Nasdaq: ASTS), based in Midland, Texas, is building what it calls a space-based cellular broadband network designed to connect everyday, unmodified smartphones directly to its satellites — aiming to eliminate mobile “dead zones” worldwide. Where Starlink began as a fixed-broadband service using dedicated terminals, AST’s entire thesis is the direct-to-device market that SpaceX’s IPO filing has now thrust into the spotlight. That makes the two natural — if vastly differently sized — competitors in the same emerging category.

The company has been building both its constellation and its commercial foundation. AST reported full-year 2025 revenue of about US$70.9 million, driven by mobile-network-operator partners and the U.S. government, and said it had secured over US$1.2 billion in aggregate contracted revenue commitments from partners — a figure that speaks to the scale of carrier interest. It has also reported completing the in-orbit unfolding of BlueBird 6, which it described as the largest commercial communications array ever deployed in low Earth orbit, and has laid out a launch cadence intended to reach 45 to 60 satellites in orbit by the end of 2026.

The risk profile is equally clear, and worth stating plainly: AST is a capital-intensive, still-largely-pre-revenue business whose value depends on executing a demanding manufacturing-and-launch campaign on schedule. A successful deployment validates the model; a stumble in cadence or array deployment would do the opposite. This is a build-it-first business, and the build is far from finished.

How AST and SpaceX Actually Differ

It would be a mistake to treat AST as a miniature Starlink. The two take different technical and commercial approaches: AST partners with terrestrial mobile-network operators to extend their existing networks from space, positioning itself as a complement that carriers integrate, rather than a stand-alone consumer ISP. SpaceX, by contrast, has the advantage of owning its own launch vehicles — it flies Starlink satellites on its own Falcon 9 and Starship rockets — plus enormous scale and a head start in subscribers. AST’s counter is focus and carrier alignment: it is building specifically for the direct-to-device use case in partnership with the incumbents whose customers it would serve. Which model wins, or whether both coexist, is exactly the open question the SpaceX IPO has made unavoidable. Tracking how this sector is being repriced in real time? Join the free Orbital Economy Signal Brief to follow the shifts as they happen.

The Wider Satellite-Connectivity Field

Beyond AST, a couple of listed satellite-connectivity companies help frame the landscape — each with a distinct model and risk profile, and neither a proxy for the other. Globalstar (Nasdaq: GSAT) provides mobile satellite services and wholesale capacity, reporting first-quarter 2026 revenue of about US$70.1 million, up 17% year-over-year, and has been a long-running infrastructure partner in the satellite-to-phone space. Viasat (Nasdaq: VSAT) anchors the broadband-and-connectivity end as a diversified satellite-communications operator serving aviation, government, and consumer markets. Together with AST, these names show that “satellite connectivity” spans several business models — wholesale capacity and diversified broadband — all being re-rated as the direct-to-device opportunity SpaceX highlighted draws fresh capital and attention. Each, however, will live or die on its own constellation, balance sheet, and execution.

A Note on the Broader Space Trade

One smaller name investors scanning the sector may note is Starfighters Space, Inc. (NYSE American: FJET), mentioned here for context only and not as a recommendation. The company has publicly described operating what it calls the world’s only commercial fleet of flight-ready Mach 2+ supersonic F-104 aircraft from NASA’s Kennedy Space Center, and in May 2026 it announced a US$17.5 million strategic equity investment led by institutional investors, with proceeds earmarked to support operational expansion and continued advancement of its STARLAUNCH platform. These are the company’s own announced figures; readers should verify them in its filings.

The Bottom Line

The SpaceX IPO did more than reveal Starlink’s economics — it confirmed that connecting ordinary phones directly to satellites is a market the most sophisticated player in space intends to pursue aggressively. For public investors, that validation lands not on SpaceX’s sprawling franchise but on the focused names building in the same direction. AST SpaceMobile is the most prominent of them, with carrier commitments and an ambitious deployment plan — and the considerable execution risk that comes with building a constellation from scratch. The question the IPO sharpened is no longer whether satellite-to-phone is real, but who builds the winning network. The answer will come from orbit, on a schedule, over the next several years. To keep a closer eye on the launch, satellite, lunar, and space-data economy as it develops, sign up for the free Orbital Economy Signal Brief.

SIGNAL OVER NOISE

Signal over noise. Space, satellite-connectivity, and telecom headlines move fast — and the crowd often moves first. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they happen, so you see the move forming instead of reading about it later. See it at eagle-eye.dev.

CONTACT

Equity Insider
[email protected]

SOURCES

[1] Space Exploration Technologies Corp. (SpaceX), Form S-1 registration statement and Starlink Mobile disclosures (proposed Nasdaq symbol SPCX), May–June 2026, sec.gov; contemporaneous news reporting.
[2] AST SpaceMobile, Inc. (Nasdaq: ASTS), Q4 and full-year 2025 results and business update, March 2, 2026.
[3] Globalstar, Inc. (Nasdaq: GSAT), Q1 2026 financial results, May 7, 2026.
[4] Viasat, Inc. (Nasdaq: VSAT), corporate disclosures, 2026.
[5] Starfighters Space, Inc. (NYSE American: FJET), company press releases ($17.5 million strategic investment; STARLAUNCH; Kennedy Space Center operations), 2026.

DISCLAIMER

IMPORTANT — PLEASE READ: This article is editorial commentary and was NOT paid for, requested, commissioned, reviewed, or approved by any of the companies named in it, nor by Creative Direct Marketing Group (“CDMG”). No company mentioned in this article paid for or had any involvement in its preparation or publication. The disclosures that follow are provided in the interest of full transparency regarding our broader business relationships, even though they do not apply to this specific article.

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This publication is neither an offer nor a recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is owned and operated by Market IQ Media Group Limited, a company incorporated under the laws of Ireland (“MIQL”). As part of its ongoing business, MIQL has been paid fees by CDMG for advertising and digital media for Starfighters Space, Inc. (NYSE American: FJET) in connection with separate, paid campaigns; those paid materials are distinct from this article, which is unpaid editorial. This relationship constitutes a potential conflict of interest as to our ability to remain objective in our commentary regarding Starfighters Space, Inc., and readers are strongly encouraged not to use this publication as the basis for any investment decision. MIQL and its owner/operators do not own shares of Starfighters Space, Inc. or of any other company named in this article in connection with this piece, but reserve the right to buy and sell securities of any company mentioned at any time without further notice. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our publication is not trustworthy unless verified by their own independent research. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

FORWARD-LOOKING STATEMENTS: This publication contains forward-looking statements concerning the companies referenced and the commercial-space sector, including statements regarding the proposed initial public offering of Space Exploration Technologies Corp. (“SpaceX”) and its reported terms, which are based on third-party reporting and SpaceX’s own filings and remain subject to change until and unless finalized; product development, launch and mission timelines; contract awards and backlog; and broader market conditions. Forward-looking statements are not guarantees of future results and are subject to risks and uncertainties — including execution, regulatory, financing, competitive and macroeconomic risks — that could cause actual results to differ materially, as detailed in each referenced company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov. References to SpaceX are for thematic and contextual purposes only; SpaceX is a separate company with no affiliation to the publisher, and nothing herein is an offer to buy or sell, or a solicitation of any offer to buy or sell, securities of SpaceX or any other company. Figures attributed to named companies are drawn from those companies’ public disclosures. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made; the publisher undertakes no obligation to update or revise them except as required by applicable law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-spacex-ipo-put-a-spotlight-on-starlink–and-on-the-one-public-company-building-a-rival-direct-to-phone-network-302812572.html

Waton Financial Launches MoTA Alpha, Marking Full Strategic Pivot to AI-Native Finance

PR Newswire

HONG KONG, June 27, 2026 /PRNewswire/ — Waton Financial Limited (NASDAQ: WTF) today announced the release of MoTA Alpha, a major upgrade to its flagship AI-powered investment platform. First unveiled in closed beta in May 2026, MoTA (Manager of Trading Agents) now introduces the Agent Talents Market, a creator ecosystem for third-party AI trading agents, alongside a redesigned multi-agent collaboration workflow and a fully overhauled user experience. The Alpha release represents more than a product milestone — it signals Waton’s decisive transition from a securities brokerage and SaaS provider into an AI-native financial technology company.

MoTA Alpha: What’s New

MoTA Alpha builds on the beta’s foundation as an AI-native investment team workbench — a platform that enables professional investors and portfolio managers to assemble, manage, and supervise teams of specialized AI agents across research, analysis, risk, and execution functions within a structured, auditable workflow, with mandatory human review and final sign-off at every stage.

Three headline upgrades define this release:

  1. Agent Talents Market
    An open marketplace where third-party developers can create, publish, and rank AI trading agents. Users subscribe to or deploy agents built by independent creators, with all agents running on Waton’s infrastructure. Agent’s internal logic remains under creator control; Waton provides the platform layer and execution environment.

  2. Enhanced Multi-Agent Collaboration
    A rebuilt task orchestration layer that improves inter-agent communication, role assignment, and decision audit trails. The result is a workflow that mirrors the dynamics of a real investment team — each agent operates within its mandate, escalates to human supervisors where required, and maintains a complete, reviewable log.

  3. Redesigned Interface
    A significantly improved user experience that preserves MoTA’s distinctive 8-bit pixel-art visual identity — a deliberate departure from the blue-and-white minimalism that dominates fintech — while increasing information density and operational speed for professional workflows.

The Strategic Pivot

MoTA Alpha represents the clearest demonstration yet of Waton’s evolution from a financial infrastructure provider into an AI-native product company.

Since its NASDAQ listing in April 2025, Waton has positioned itself as the world’s first publicly traded AI agent holding company. Yet its revenue base has remained rooted in traditional securities brokerage and Broker Cloud SaaS solutions serving institutional clients in Hong Kong. MoTA Alpha changes that equation: AI is no longer a narrative layer on top of an existing brokerage business — it is now a tangible, independently monetizable product line.

The company is structuring itself around a “brokerage infrastructure + AI application” dual-engine model. This is a meaningfully different profile from either pure-play online brokers or conventional fintech SaaS firms, positioning Waton closer to the emerging category of AI-native financial platforms.

Financial Foundation

According to Waton’s unaudited financial results for the first half of fiscal year 2026 (six months ended September 30, 2025), total revenues rose 106.3% year-on-year to $6.10 million, driven by a 223.1% increase in brokerage and commission income to $4.17 million. Cash and segregated cash stood at $29.88 million, with total assets of $68.98 million.

Notably, the company reported research and development expenses as a standalone line item for the first time ($0.39 million in H1 FY2026), alongside significant share-based compensation tied to AI product development. MoTA Alpha is the first scaled output of this R&D pipeline.

Management Commentary

“The Alpha release of MoTA marks Waton’s evolution from a financial technology services provider to an AI-era infrastructure and product company,” said Zhou Kai (Tony Zhou), Chairman and Chief Technology Officer of Waton Financial. “We are not building a chatbot for trading. We are building a platform where professional investors manage teams of AI agents — each with defined roles, clear accountability, and human oversight. The Agent Talents Market extends this further: MoTA transitions from a product into an ecosystem.”

Roadmap

Following the Alpha release, Waton expects to open MoTA to public beta testing in Q3 2026. The platform currently supports Hong Kong and U.S. equity markets, with digital asset coverage on the product roadmap. MoTA is available as a standalone application at m.mota.ai and integrates with Waton’s existing brokerage and TradingWTF infrastructure.

For investors tracking $WTF, MoTA Alpha serves as the first real test of whether the “AI agent holding company” thesis translates from corporate positioning into a durable commercial model.

Media Contact

https://www.wtf.us


https://www.mota.ai 

About Waton Financial Limited

Waton Financial Limited (NASDAQ: WTF) is the world’s first NASDAQ-listed AI agent holding company, dedicated to discovering, creating, investing in, and incubating AI agents that work for people. Its flagship product, MoTA (Manager of Trading Agent), enables professional investors to build, manage, and supervise teams of specialized AI agents within a structured, human-supervised workflow. The company also empowers global brokerage firms and financial institutions through Broker Cloud + SaaS + AI digital solutions. Learn more at https://wtf.us.

Cision View original content:https://www.prnewswire.com/news-releases/waton-financial-launches-mota-alpha-marking-full-strategic-pivot-to-ai-native-finance-302812548.html

SOURCE Waton Financial Limited

Veritone Deadline: VERI Investors with Losses in Excess of $100K Have Opportunity to Lead Veritone, Inc. Securities Fraud Lawsuit

PR Newswire

NEW YORK, June 26, 2026 /PRNewswire/ —

Rosen Law Firm Logo

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Veritone, Inc. (NASDAQ: VERI) between October 14, 2025 and April 14, 2026, inclusive (the “Class Period”), of the important July 20, 2026 lead plaintiff deadline.

So what: If you purchased Veritone securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Veritone class action, go to https://rosenlegal.com/cases/veritone-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Veritone inaccurately recorded and/or misclassified certain revenue and costs; (2) as a result, Veritone overstated its revenue, assets, accounts receivable, royalties and other comprehensive income; (3) Veritone maintained deficient internal controls over accounting and financial reporting; (4) as a result of the foregoing, Veritone would be forced to restate certain of its financial statements; and (5) as a result, defendants’ positive statements about Veritone’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Veritone class action, go to https://rosenlegal.com/cases/veritone-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/veritone-deadline-veri-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-veritone-inc-securities-fraud-lawsuit-302812376.html

SOURCE THE ROSEN LAW FIRM, P. A.

PicS N.V. Notice of August 4, 2026 Application Deadline for Class Action Lawsuit – Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

PR Newswire

NEW YORK and NEW ORLEANS, June 26, 2026 /PRNewswire/ — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in PicS N.V. (“PicS” or the “Company”) (NasdaqGS: PICS) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of PicS who were adversely affected if they purchased the Company’s Class A common stock in and/or traceable to its January 30, 2026 initial public offering (the “IPO”). This action is pending in the United States District Court for the Southern District of New York.

Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-pics/?prs=globe

PicS investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-pics/?prs=globe to learn more.

CASE DETAILS: According to the Complaint, PicS and certain of its executives are charged with failing to disclose material information in the Offering Documents, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (i) in December 2025, the Company determined that its credit assessment procedures were deficient and required enhancement; (ii) following implementation of revised procedures, the Company reclassified approximately R$590 million of exposures from Stage 2 to Stage 3, resulting in an incremental ECL charge of R$88 million for the quarter ended December 31, 2025; (iii) the Company experienced an undisclosed Stage 3 formation rate exceeding 7% in the fourth quarter of 2025, materially departing from the historical trends disclosed in the offering documents; (iv) the offering documents materially overstated the effectiveness of PicS N.V.’s credit models, user data, and underwriting and risk-monitoring capabilities; and (v) prior to the IPO, PicS N.V.’s expansion into riskier business lines had led to deteriorating credit quality, increased default and impairment risk, and adverse financial and operational trends that were expected to continue worsening and materially impact the Company’s business and financial results. 

The case is FirstFire Global Opportunities Fund, LLC v. PicS N.V., No. 26-cv-04793.

WHAT TO DO? If you invested in PicS and suffered a loss during the relevant time frame, you have until August 4, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pics-nv-notice-of-august-4-2026-application-deadline-for-class-action-lawsuit—contact-lewis-kahn-esq-at-kahn-swick–foti-llc-before-application-deadline-302812310.html

SOURCE ClaimsFiler

GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

PR Newswire

NEW YORK and NEW ORLEANS, June 26, 2026 /PRNewswire/ — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings Corp. (NasdaqGS: WGS) (“GeneDx” or the “Company”), if they purchased or otherwise acquired the Company’s shares between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Connecticut.

What You May Do

If you purchased shares of GeneDx as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-wgs/?prs=globe to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 3, 2026.

>>>

CLICK HERE

for more information

About the Lawsuit

GeneDx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

On May 4, 2026, the Company reported its financial results for the first quarter of fiscal year 2026, disclosing a drop in adjusted gross margin from 74% to 69%, that it had missed its revenue estimates for both its exome and genome lines, and lowered its guidance for full year revenue to $475 – $490 million, down from $540 – $550 million. The Company also disclosed a $31.2 million impairment loss attributable to its prior acquisition of Fabric Genomics, an AI-driven genomic interpretation company, which the Company had touted as expected to expand its addressable market through multiple scalable revenue streams and transform static data into a recurring revenue-generating platform.

On this news, the price of GeneDx shares fell by $33.42 per share, or 49.2%.

The case is Basma v. GeneDx Holdings Corp., No. 26-cv-00880.

>>>To Learn More, Click

HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click

HERE

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/genedx-holdings-securities-fraud-class-action-result-of-acquisition-performance-misrepresentations-and-49-stock-decline—investors-may-contact-lewis-kahn-esq-at-kahn-swick–foti-llc-302812341.html

SOURCE Kahn Swick & Foti, LLC